Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein e null mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 2, 2010, Pages 260-268

  Narasimha, Ajay J ^a   Watanabe, Junji ^b   Ishikawa, Tomo O ^a   Priceman, Saul J ^a   Wu, Lily ^a   Herschman, Harvey R ^a   Reddy, Srinivasa T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine/Cardiology   (United States)

Author keywords

Atherosclerosis; Cyclooxygenase 2; Inflammation; Myeloid cells; Prostanoids

Indexed keywords

APOLIPOPROTEIN E; BETA ACTIN; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; PROSTANOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL MOTILITY; CELL POPULATION; CONTROLLED STUDY; DISEASE COURSE; HYPERLIPIDEMIA; INFLAMMATION; LYMPHOID CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; CYCLOOXYGENASE 2; DIETARY FATS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75149183197     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.198762     Document Type: Article

References (46)

1. Lusis AJ. Atherosclerosis. Nature 2000, 407; 233-241.
2. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-2838.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
4. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365-375.
5. Linton MF, Fazio S Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S35-S40.
6. Vanderlaan PA, Reardon CA. Thematic review series: the immune system and atherogenesis. The unusual suspects: an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res. 2005;46: 829-838.
7. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547-1560.
8. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta. 1996; 1299:125-140.
9. Cuccurullo C, Fazia ML, Mezzetti A, Cipollone F. COX-2 expression in atherosclerosis: the good, the bad or the ugly? Curr Med Chem. 2007; 14:1595-1605.
10. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
11. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation. 2003;108:3017-3023.
12. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296: 1633-1644.
13. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959. (Pubitemid 33010342)
14. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028-1035.
15. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
16. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39:443-452.
17. Jacob S, Laury-Kleintop L, Lanza-Jacoby S. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-mice. J Surg Res. 2008;146:135-142.
18. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, Epstein SE. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol. 2003; 41:1812-1819.
19. Olesen M, Kwong E, Meztli A, Kontny F, Seljeflot I, Arnesen H, Lyngdorf L, Falk E. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J. 2002;36: 362-367.
20. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA. 2001;98: 3358-3363.
21. Bea F, Blessing E, Bennett BJ, Kuo CC, Campbell LA, Kreuzer J, Rosenfeld ME. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res. 2003;60:198-204.
22. Paramo JA, Rodriguez JA, Beloqui O, Orbe J. Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis? Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:303-311.
23. Ishikawa TO, Herschman HR. Conditional knockout mouse for tissue-specific disruption of the cyclooxygenase-2 (Cox-2) gene. Genesis. 2006; 44:143-149.
24. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265-277.
25. Ishikawa TO, Jain NK, Taketo MM, Herschman HR. Imaging cyclooxygenase-2 (Cox-2) gene expression in living animals with a luciferase knock-in reporter gene. Mol Imaging Biol. 2006;8:171-187.
26. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68: 231-240.
27. Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem. 1993;268:20676-20682.
28. Gilroy DW, Colville-Nash PR. New insights into the role of COX 2 in inflammation. J Mol Med. 2000;78:121-129.
29. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxy-genase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA. 1994;91:3228-3232.
30. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330-335.
31. Hedin U, Roy J, Tran PK. Control of smooth muscle cell proliferation in vascular disease. Curr Opin Lipidol. 2004;15:559-565.
32. Barbieri SS, Eligini S, Brambilla M, Tremoli E, Colli S. Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte to macro-phage differentiation: critical role of NADPH oxidase. Cardiovasc Res. 2003;60:187-197.
33. Tuomisto TT, Riekkinen MS, Viita H, Levonen AL, Yla-Herttuala S. Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading-cDNA and protein array study. Atherosclerosis. 2005;180:283-291.
34. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther. 2008;118:161-180.
35. Everts B, Wahrborg P, Hedner T. COX-2-Specific inhibitors-the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol. 2000;19:331-343.
36. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007;50:470-479.
37. Ejima K, Layne MD, Carvajal IM, Kritek PA, Baron RM, Chen YH, Vom Saal J, Levy BD, Yet SF, Perrella MA. Cyclooxygenase-2-deficient mice are resistant to endotoxin-induced inflammation and death. Faseb J. 2003;17:1325-1327.
38. Posadas I, Terencio MC, Guillen I, Ferrandiz ML, Coloma J, Paya M, Alcaraz MJ. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn Schmiedebergs Arch Pharmacol. 2000;361:98-106. (Pubitemid 30064661)
39. Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol. 1999;126:1200-1204.
40. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prosta-glandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104: 921-927.
41. Narasimha A, Watanabe J, Lin JA, Hama S, Langenbach R, Navab M, Fogelman AM, Reddy ST. A novel anti-atherogenic role for COX-2-potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat. 2007;84:24-33.
42. Reiss AB, Edelman SD. Recent insights into the role of prostanoids in atherosclerotic vascular disease. Curr Vasc Pharmacol. 2006;4: 395-408.
43. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev. 2006; 58:375-388.
44. Nowak J, FitzGerald GA. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest. 1989; 83:380-385.
45. Reddy ST, Herschman HR. Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospho-lipase A2 and distal prostaglandin synthase 1. J Biol Chem. 1996;271: 186-191.
46. Liu T, Stern A, Roberts LJ, Morrow JD. The isoprostanes: novel prosta-glandin-like products of the free radical-catalyzed peroxidation of ara-chidonic acid. J Biomed Sci. 1999;6:226-235.